369 related articles for article (PubMed ID: 28408400)
21. DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia.
Ferreira HJ; Heyn H; Vizoso M; Moutinho C; Vidal E; Gomez A; Martínez-Cardús A; Simó-Riudalbas L; Moran S; Jost E; Esteller M
Oncogene; 2016 Jun; 35(23):3079-82. PubMed ID: 26434589
[TBL] [Abstract][Full Text] [Related]
22. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
[TBL] [Abstract][Full Text] [Related]
23. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
[TBL] [Abstract][Full Text] [Related]
24. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
[TBL] [Abstract][Full Text] [Related]
25. Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia.
Jost E; Lin Q; Weidner CI; Wilop S; Hoffmann M; Walenda T; Schemionek M; Herrmann O; Zenke M; Brümmendorf TH; Koschmieder S; Wagner W
Leukemia; 2014 Jun; 28(6):1227-34. PubMed ID: 24280869
[TBL] [Abstract][Full Text] [Related]
26. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
Ribeiro AF; Pratcorona M; Erpelinck-Verschueren C; Rockova V; Sanders M; Abbas S; Figueroa ME; Zeilemaker A; Melnick A; Löwenberg B; Valk PJ; Delwel R
Blood; 2012 Jun; 119(24):5824-31. PubMed ID: 22490330
[TBL] [Abstract][Full Text] [Related]
27. Growth disrupting mutations in epigenetic regulatory molecules are associated with abnormalities of epigenetic aging.
Jeffries AR; Maroofian R; Salter CG; Chioza BA; Cross HE; Patton MA; Dempster E; Temple IK; Mackay DJG; Rezwan FI; Aksglaede L; Baralle D; Dabir T; Hunter MF; Kamath A; Kumar A; Newbury-Ecob R; Selicorni A; Springer A; Van Maldergem L; Varghese V; Yachelevich N; Tatton-Brown K; Mill J; Crosby AH; Baple EL
Genome Res; 2019 Jul; 29(7):1057-1066. PubMed ID: 31160375
[TBL] [Abstract][Full Text] [Related]
28. DNMT3A in Leukemia.
Brunetti L; Gundry MC; Goodell MA
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28003281
[TBL] [Abstract][Full Text] [Related]
29. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Signal; 2023 May; 105():110626. PubMed ID: 36758683
[TBL] [Abstract][Full Text] [Related]
30. Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML.
Li S; Chen X; Wang J; Meydan C; Glass JL; Shih AH; Delwel R; Levine RL; Mason CE; Melnick AM
Cancer Discov; 2020 Dec; 10(12):1934-1949. PubMed ID: 32938585
[TBL] [Abstract][Full Text] [Related]
31. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.
Russler-Germain DA; Spencer DH; Young MA; Lamprecht TL; Miller CA; Fulton R; Meyer MR; Erdmann-Gilmore P; Townsend RR; Wilson RK; Ley TJ
Cancer Cell; 2014 Apr; 25(4):442-54. PubMed ID: 24656771
[TBL] [Abstract][Full Text] [Related]
32. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
Falini B; Sportoletti P; Brunetti L; Martelli MP
Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
[TBL] [Abstract][Full Text] [Related]
33. GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations.
Perugini M; Iarossi DG; Kok CH; Cummings N; Diakiw SM; Brown AL; Danner S; Bardy P; Bik To L; Wei AH; Lewis ID; D'Andrea RJ
Leukemia; 2013 Jul; 27(7):1588-92. PubMed ID: 23187294
[No Abstract] [Full Text] [Related]
34. Investigating the potential role of genetic and epigenetic variation of DNA methyltransferase genes in hyperplastic polyposis syndrome.
Drini M; Wong NC; Scott HS; Craig JM; Dobrovic A; Hewitt CA; Dow C; Young JP; Jenkins MA; Saffery R; Macrae FA
PLoS One; 2011 Feb; 6(2):e16831. PubMed ID: 21347319
[TBL] [Abstract][Full Text] [Related]
35. MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML.
Sanders MA; Chew E; Flensburg C; Zeilemaker A; Miller SE; Al Hinai AS; Bajel A; Luiken B; Rijken M; Mclennan T; Hoogenboezem RM; Kavelaars FG; Fröhling S; Blewitt ME; Bindels EM; Alexander WS; Löwenberg B; Roberts AW; Valk PJM; Majewski IJ
Blood; 2018 Oct; 132(14):1526-1534. PubMed ID: 30049810
[TBL] [Abstract][Full Text] [Related]
36. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.
Liang DC; Liu HC; Yang CP; Jaing TH; Hung IJ; Yeh TC; Chen SH; Hou JY; Huang YJ; Shih YS; Huang YH; Lin TH; Shih LY
Blood; 2013 Apr; 121(15):2988-95. PubMed ID: 23365461
[TBL] [Abstract][Full Text] [Related]
37. Functional and epigenetic phenotypes of humans and mice with DNMT3A Overgrowth Syndrome.
Smith AM; LaValle TA; Shinawi M; Ramakrishnan SM; Abel HJ; Hill CA; Kirkland NM; Rettig MP; Helton NM; Heath SE; Ferraro F; Chen DY; Adak S; Semenkovich CF; Christian DL; Martin JR; Gabel HW; Miller CA; Ley TJ
Nat Commun; 2021 Jul; 12(1):4549. PubMed ID: 34315901
[TBL] [Abstract][Full Text] [Related]
38. DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias.
Yang L; Rodriguez B; Mayle A; Park HJ; Lin X; Luo M; Jeong M; Curry CV; Kim SB; Ruau D; Zhang X; Zhou T; Zhou M; Rebel VI; Challen GA; Gottgens B; Lee JS; Rau R; Li W; Goodell MA
Cancer Cell; 2016 Jun; 29(6):922-934. PubMed ID: 27300438
[TBL] [Abstract][Full Text] [Related]
39. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
40. DNMT3A mutations in acute myeloid leukemia.
Shah MY; Licht JD
Nat Genet; 2011 Mar; 43(4):289-90. PubMed ID: 21445072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
